Dokumentenart: | Artikel | ||||
---|---|---|---|---|---|
Titel eines Journals oder einer Zeitschrift: | Archiv der Pharmazie | ||||
Verlag: | Wiley | ||||
Band: | 328 | ||||
Nummer des Zeitschriftenheftes oder des Kapitels: | 7-8 | ||||
Seitenbereich: | S. 595-603 | ||||
Datum: | 1995 | ||||
Zusätzliche Informationen (Öffentlich): | CAN 123:245214 78-7 Inorganic Chemicals and Reactions 168700-16-1P; 168700-17-2P; 168700-18-3P; 168700-19-4P; 168700-20-7P; 168700-21-8P; 168700-22-9P; 168700-23-0P Role: BAC (Biological activity or effector, except adverse), BSU (Biological study, unclassified), SPN (Synthetic preparation), BIOL (Biological study), PREP (Preparation) (prepn. and antitumor activity of); 459-57-4 (4-Fluorobenzaldehyde); 603-35-0 (Triphenylphosphine); 824-98-6 (3-Methoxybenzyl chloride); 10025-99-7 (Potassium tetrachloroplatinate (K2PtCl4) Role: RCT (Reactant), RACT (Reactant or reagent) (prepn. of fluorophenyl- and difluorophenyl(phenyl)ethylenediamine deriv. diastereomers and their platinum complexes as antitumor agents); 18880-05-2P (3-Methoxybenzyltriphenylphosphonium chloride); 168700-04-7P; 168700-05-8P; 168700-06-9P; 168700-07-0P; 168700-08-1P; 168700-09-2P; 168700-10-5P; 168700-11-6P; 168700-12-7P; 168700-13-8P; 168700-14-9P; 168700-15-0P; 168700-26-3P; 168700-27-4P; 168700-28-5P (4-Fluoro-3'-methoxystilbene); 168700-29-6P; 168958-79-0P; 168958-80-3P; 168958-81-4P; 168958-82-5P Role: RCT (Reactant), SPN (Synthetic preparation), PREP (Preparation), RACT (Reactant or reagent) (prepn. of fluorophenyl- and difluorophenyl(phenyl)ethylenediamine deriv. diastereomers and their platinum complexes as antitumor agents); 168700-24-1P; 168700-25-2P; 168958-83-6P; 168958-84-7P Role: SPN (Synthetic preparation), PREP (Preparation) (prepn. of fluorophenyl- and difluorophenyl(phenyl)ethylenediamine deriv. diastereomers and their platinum complexes as antitumor agents) | ||||
Institutionen: | Chemie und Pharmazie > Institut für Pharmazie > Entpflichtete oder im Ruhestand befindliche Professoren > Prof. Schönenberger Chemie und Pharmazie > Institut für Pharmazie > Lehrstuhl Pharmazeutische / Medizinische Chemie II (Prof. Buschauer) | ||||
Projekte: | SFB 234 | ||||
Identifikationsnummer: |
| ||||
Stichwörter / Keywords: | Neoplasm inhibitors Role: BAC (Biological activity or effector, except adverse), BSU (Biological study, unclassified), SPN (Synthetic preparation), BIOL (Biological study), PREP (Preparation) (mammary gland, prepn. of fluorophenyl- and difluorophenyl(ph Mammary gland Role: BAC (Biological activity or effector, except adverse), BSU (Biological study, unclassified), SPN (Synthetic preparation), BIOL (Biological study), PREP (Preparation) (neoplasm, inhibitors, prepn. of fluorophenyl- and difluorophenyl(p platinum fluorophenylethylenediamine deriv diastereomer prepn antitumor antitumor breast platinum fluorophenylethylenediamine deriv diastereomer | ||||
Dewey-Dezimal-Klassifikation: | 500 Naturwissenschaften und Mathematik > 540 Chemie | ||||
Status: | Veröffentlicht | ||||
Begutachtet: | Ja, diese Version wurde begutachtet | ||||
An der Universität Regensburg entstanden: | Ja | ||||
Dokumenten-ID: | 17708 |
Zusammenfassung
The diastereomeric 1-(fluoro/difluorophenyl)-2-phenylethylene-diamines (4-fluoro: erythro-1/threo-1; 2,4-difluoro: erythro-2/-threo-2; 2,6-difluoro: erythro-3/threo-3) and the diastereomeric 1-(4-fluorophenyl)-2-(3-hydroxyphenyl)ethylenediamines (erythro-4/-threo-4) were synthesized from appropriately substituted stilbenes by reaction with IN3 and subsequent LiAlH4 redn. Coordination of the ...
Zusammenfassung
The diastereomeric 1-(fluoro/difluorophenyl)-2-phenylethylene-diamines (4-fluoro: erythro-1/threo-1; 2,4-difluoro: erythro-2/-threo-2; 2,6-difluoro: erythro-3/threo-3) and the diastereomeric 1-(4-fluorophenyl)-2-(3-hydroxyphenyl)ethylenediamines (erythro-4/-threo-4) were synthesized from appropriately substituted stilbenes by reaction with IN3 and subsequent LiAlH4 redn. Coordination of the 1,2-diphenylethylenediamines to Pt was carried out using K2PtI4. The water sol. aquasulfato-Pt(II) complexes (erythro/threo-1-PtSO4-erythro/threo-4-PtSO4) were obtained from the diiodoplatinum(II) complexes by reaction with Ag2SO4. Addnl. erythro/threo-1-PtSO4 and erythro/threo-4-PtSO4 were transformed into the dichloroplatinum(II) complexes (erythro/threo-1-PtCl2, erythro/threo-4-PtCl2) by treatment with KCl. In contrast to the less effective erythro-configurated sulfatoplatinum(II) complexes the threo-analogs showed comparable or even superior activities to cisplatin on the human MDA-MB-231 breast cancer cell line. On the MXT-M-3.2 breast cancer of the mouse only erythro- and threo-4-PtSO4 caused similar effects like cisplatin. The strong inhibitory effect of the diastereomeric sulfatoplatinum(II) complexes on the P-388 leukemia of the mouse was equal to that of cisplatin. On the latter tumor threo-4-PtCl2 was the most active among the less toxic dichloroplatinum(II) derivs.
Metadaten zuletzt geändert: 24 Mai 2018 12:18